Achin Gupta is set to become the next Managing Director and Global CEO of Cipla, kicking off a structured transition at the major pharma firm. Gupta, currently the Chief Operating Officer, will step into the MD and global CEO role on April 1, 2026, subject to shareholder approval. He will serve as CEO-designate from January 2026.
His appointment follows Umang Vohra’s decision to step down after leading the company for nearly ten years. During Vohra’s tenure, Cipla sharpened its position in India, expanded in the US market, and invested in building a leadership pipeline, a point he underlined while addressing reporters after the announcement.
Vohra noted that the organisation “is ready for the future” and emphasised that he does not expect any leadership vacuum post his exit. He did not disclose his next move, adding that any continued involvement with Cipla would depend on the board’s decision.
Gupta joined Cipla in 2021 and previously led its One India business. As COO, he has overseen commercial markets, manufacturing, supply chain and APIs. Before Cipla, he worked with Glenmark Pharma.
The change of guard comes at a time when Cipla is navigating a shifting global pharma environment, including pricing pressures in the US generics market and tapering contribution from cancer drug Revlimid, ahead of its patent expiry.
The announcement coincided with Cipla’s Q2 results. The company posted an 8% year-on-year rise in revenue to ₹7,589 crore and a net profit increase of 4% to ₹1,351 crore. Key brands in respiratory and consumer health continued to deliver growth, while the company also announced a partnership to market Eli Lilly’s weight-management drug Tirzepatide in India.
Cipla appoints Achin Gupta as next MD & GCEO as Umang Vohra steps down
